

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

### Sofosbuvir-based treatment, neutralisation against Omicron from previous non-Omicron infection, long COVID in adolescents

#### Peer reviewed journals featured:

- A systematic review on the efficacy of sofosbuvir-based treatment in COVID-19 patients [here](#)
- Randomised clinical trials of:
  - Niclosamide vs placebo in SARS-CoV-2 respiratory viral clearance, shedding and duration of symptoms in patients with mild to moderate COVID-19 [here](#)
- Observational studies on:
  - Neutralisation against Omicron from previous non-Omicron infection [here](#)
  - Prognostic accuracy of triage tools for suspected COVID-19 in a prehospital setting [here](#)
  - Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK) [here](#)
  - Physical and mental health 3 months after SARS-CoV-2 infection (long COVID-19) in adolescents in England (CLOCK) [here](#)
  - Vaccine effectiveness of heterologous CoronaVac plus Comirnaty (Pfizer) in Brazil [here](#)
- An editorial on African vaccine manufacturing [here](#)

#### Letters and correspondence discussed:

- Post-recovery enhancement of anti-variant neutralisation after severe COVID-19 [here](#)
- Exempting healthcare workers recovered from natural SARS-CoV-2 infection from mandatory vaccination [here](#)

#### Pre-peer review articles featured:

- Quantifying the risks versus benefits of the Comirnaty (Pfizer) vaccine in Australia [here](#)
- Anti-spike antibody trajectories in people previously immunised with Comirnaty (Pfizer) or Vaxzevria (AstraZeneca) after a Comirnaty (Pfizer) booster dose [here](#)
- A machine learning algorithm for diagnosing paediatric patients with multisystem inflammatory syndrome and Kawasaki disease [here](#)
- Duration of protection of mRNA vaccines against symptomatic Omicron infection in Qatar [here](#)
- Hospitalised vaccine-breakthrough COVID-19 cases compared with contemporary unvaccinated hospitalised adults [here](#)

## Guidance and reports

- The Therapeutic Goods Administration (TGA) issued provisional approval for booster dose of Vaxzevria (AstraZeneca) COVID-19 vaccine for adults 18 years and older [here](#)

## News and blogs

- The UK government plans to remove all remaining restrictions in England a month early [here](#)
- A winter Olympics amid “zero covid” [here](#)

[Click here](#) to subscribe to the daily evidence digest.

## Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).